Concentrated Valproic Acid for Rapid Emergency Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for traumatic brain injury (TBI) and emergency injuries are largely supportive and do not effectively improve survival or reduce brain damage, with existing valproic acid formulations requiring multiple vials and lengthy infusion times, posing challenges in rapid and effective high-dose delivery, especially in field settings where time is critical and bacterial contamination risks are high.
Innovation Solution
Development of concentrated valproic acid pharmaceutical compositions for rapid delivery via intraosseous or intravenous routes, providing high doses (up to 150 mg/kg) within a short time frame (e.g., 2-3 hours) using formulations with concentrations of 100 mg/ml to 500 mg/ml, ensuring stability at room temperature and reducing the need for multiple vials, thus minimizing preparation time and contamination risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional valproic acid formulations are used, then multiple vials and lengthy infusion times are required, but this increases preparation time and bacterial contamination risks
Solution Approach 1:
The patent combines multiple vials of conventional valproic acid formulation into a single concentrated formulation containing the equivalent dose, eliminating the need for multiple connections and reducing preparation time while minimizing contamination risk
2Productivity
If concentrated valproic acid formulations are used, then rapid delivery of high doses is achieved, but formulation stability and safety must be maintained
Solution Approach 1:
The patent changes the concentration parameter of valproic acid from conventional levels to highly concentrated formulations (containing pharmacologically effective amounts in single-dose volumes), enabling rapid delivery while maintaining stability through controlled formulation conditions
3Reliability
If high doses of valproic acid are administered rapidly, then survival improvement and brain damage reduction are achieved, but the complexity of formulation and administration increases
Solution Approach 1:
The patent segments the administration process into a single-dose concentrated formulation that can be delivered through standard intravenous or intraosseous routes, maintaining simplicity despite the high dose requirement
Data Source
AI summary
Provided herein are pharmaceutical compositions comprising concentrated valproic acid (e.g., >200 mg/mL) for rapid delivery of high doses (e.g., 100-200 mg/kg) of valproic acid to subjects (e.g., intraosseous, intravenous, etc.), and methods of treating emergency injuries and conditions therewith.